Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATN-103 Extension Study in RA
NCT01063803Phase 2Completed
- Sponsor
- Sanofi
- Start
- Feb 2010
- Primary completion
- Feb 2012
- Modality
- Recombinant Proteins and Enzymes, Nanobodies (VHH)
- Countries
- 8
01
Overview
Phase 2, open-label trial of ozoralizumab in rheumatoid arthritis (RA) (2 arms), sponsored by Sanofi. Primary endpoint: Collection of safety data and assessments at 18 months. Started Feb 2010; status: completed.
02
Drugs
ozoralizumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT01063803.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01063803.